Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
| Brand name | DULOXETINE |
| Generic name | DULOXETINE HYDROCHLORIDE |
| Active ingredient(s) | DULOXETINE HYDROCHLORIDE |
| Distributed by / for | BPI |
| NDC | 51991-746-05 |
| Full product label | Duloxetine Delayed-Release Capsules, USP, 20mg, Rx Only, 500-count bottles, Mfr. by: Towa Pharmaceutical Europe, S.L. Distributed by: BPI, NDC 51991-746-05. |
| Recalling firm | Breckenridge Pharmaceutical, Inc |
| Distribution | Product was distributed nationwide within the United States |
| Quantity | 7,107 bottles |
| Recall initiated | 2024-10-10 |
| Report date | 2024-10-23 |
| Recall completed | — |
| Recall number | D-0009-2025 |
| Classification | Class II |
| FDA status | Completed |
| Origin on file | Berlin CT United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗